A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Narsoplimab (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
- Sponsors Omeros Corporation
Most Recent Events
- 06 Dec 2023 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 08 Nov 2022 New trial record
- 03 Nov 2022 According to Omeros Corporation media release, trial in progress data from this trial will be presented at 64th American Society of Hematology (ASH) Annual Meeting; The following abstracts were published today and are now available on the ASH website at www.hematology.org: